TC BioPharm Ltd (TCBP) - Cash Funds per Share

TC Biopharm is developing a proprietary T-cell therapy against leukemia, with its progress at the FDA impacting share prices. The cash per share metric demonstrates liquidity, where 42.20 determines the latest valuation figure. Experienced management is advancing oncological innovations, while operational activities are strictly limited by medical regulations regarding the disposal of biomaterials.
Comprehensive metric breakdowns and analytics for TC BioPharm (TCBP)

This indicator determines the volume of liquid assets per common share. Investors utilize this metric to assess the internal financial reserve and the company's capacity for autonomous development. Analyzing the cash position per share allows for an evaluation of the capital's margin of safety. For TC Biopharm (TCBP), this resource is critically important when scaling its allogeneic platform. These funds facilitate the expansion of gamma-delta T-cell drugs within the immunopharmaceuticals segment.